Pfizer's data could help reassure regulators of its drug's benefit after Merck disclosed smaller-than-expected benefits for its drug in final testing. (File)
Pfizer Inc is in discussions with 90 countries over supply contracts for its experimental Covid-19 pill, which was shown to reduce by 89% the risk of hospitalisation or death in patients at high risk of severe illness, Chief Executive Officer Albert Bourla said in an interview on Friday.
He said Pfizer expects to price its treatment, called Paxlovid, close to where rival Merck & Co Inc has priced its oral antiviral drug candidate.
You’ve Read Your Free Stories For Now
Sign up and keep reading more stories that matter to you.
